Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Moodys
McKesson
Merck
Dow

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

PATANASE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Patanase patents expire, and what generic alternatives are available?

Patanase is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty countries.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

Drug patent expirations by year for PATANASE
Drug Prices for PATANASE

See drug prices for PATANASE

Drug Sales Revenue Trends for PATANASE

See drug sales revenues for PATANASE

Recent Clinical Trials for PATANASE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Glenmark Pharmaceuticals Ltd. IndiaPhase 2
Alcon ResearchPhase 4
Alcon ResearchPhase 2

See all PATANASE clinical trials

Recent Litigation for PATANASE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Alcon Manufacturing Ltd. v. Barr Laboratories Inc.2007-11-07
ALCON MANUFACTURING, LTD v. APOTEX INC.2006-11-15

See all PATANASE litigation

Pharmacology for PATANASE
Synonyms for PATANASE
(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid hydrochloride
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride ;Olopatadine HCL
(Z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid hydrochloride
[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid hydrochloride
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride
113806-05-6 (Parent)
140462-76-6
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;hydrochloride
2XG66W44KF
AB0107085
AB2000599
AC1NR00D
AKOS015895232
AKOS025149118
AL-4943A
Allelock
Allelock (TN)
ALO 4943A
ALO-4943A
ALO4943A
BCP9001022
C-21208
CAS-140462-76-6
CCG-101141
CHEBI:31933
CHEMBL1719
CPD000469220
CS-2532
D01192
DE 114
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
DSSTox_CID_26486
DSSTox_GSID_46486
DSSTox_RID_81657
DTXSID0046486
EX-A1347
H06O056
HCl of KW 4679
HVRLZEKDTUEKQH-NOILCQHBSA-N
HY-B0426A
KS-1228
KW 4679
KW-4679
KW4679
LS-61598
MFCD00875716
MLS001401465
MolPort-003-986-408
NC00391
NCGC00164623-01
NCGC00263532-01
O-PPDS
O0361
Olopatadine (hydrochloride)
OLOPATADINE HCl
Olopatadine Hydrochlorde
OLOPATADINE HYDROCHLORIDE
Olopatadine hydrochloride (JP17/USAN)
Olopatadine hydrochloride (Opatanol)
Olopatadine hydrochloride [USAN:USP]
Olopatadine hydrochloride tablets (JP17)
Olopatadine hydrochloride, >=98% (HPLC)
Olopatadine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Olopax
Olopine
Opatanol
Opatanol (TN)
Opatanol;Pataday;Patanase;Allelock
Pataday
Patadine
Patanol (TN)
Pazeo
PubChem18816
Q-201511
s2494
SAM001246802
SCHEMBL23213
SMR000469220
SR-01000763388
SR-01000763388-4
TL8000904
Tox21_112242
Tox21_112242_1
UNII-2XG66W44KF
Paragraph IV (Patent) Challenges for PATANASE
Tradename Dosage Ingredient NDA Submissiondate
PATANASE SPRAY, METERED;NASAL olopatadine hydrochloride 021861 2009-06-29

US Patents and Regulatory Information for PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for PATANASE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0799044 02C0040 France   Start Trial PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.